According to the published papers, PBT2 works in Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa, erythromycin-resistant group A Streptococcus (GAS), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) and gonorrhea. PBT2 makes the development of cross-resistance to medically important antimicrobials unlikely.
There are some leftovers, but it may be that they are not yet been tested. Pfizer and Novartis are the 2 biggest antibiotic producers and they have also enough money to get the PBT2 deal, TEVA is the 3rd but clearly smaller. Pfizer has been growing a lot last year ( COVID vaccination boom) and I think it is today the strongest of these candidates. An 8 billion growing market will interest all manufacturers.
The food industry will most likely also be using PBT2, but I have no understanding of those players. These 3 are not in that business.
Antibiotic resistance fund aims 2-4 new antibiotics by 2030, page-4
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 96988980 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 655773 | 2 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |